Tralokinumab: Exploring the Potential of LP 0162 and CAT-354 Tralokinumab, previously known as LP 0162 and CAT-354, represents a promising approach for chronic dermatitis. This monoclonal antibody targets IL-13, a key driver involved in the pathogenesis of the condition . Clinical trials have demonstrated substantial improvements in … Read More

Cergutuzumab Amunaleukin: A New Frontier in Cancer Therapy? This innovative treatment, this agent, presents an potential area for tumor therapy. This construct merges a monoclonal antibody directed at this protein using amunaleukin ``` Advanced Therapy: Exploring CEA-IL2 variant plus Outside The landscape o… Read More